Recursion Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 572

Employees

  • Stock Symbol
  • RXRX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $9.26
  • (As of Friday Closing)

Recursion Pharmaceuticals General Information

Description

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 41 South Rio Grande Street
  • Salt Lake City, UT 84101
  • United States
+1 (385) 000-0000

Recursion Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recursion Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.26 $9.44 $4.97 - $16.75 $2.2B 238M 4.92M -$1.62

Recursion Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,998,600 1,792,670 1,059,019 2,321,561
Revenue 45,233 43,876 39,681 10,000
EBITDA (349,310) (326,745) (233,919) (175,195)
Net Income (354,112) (328,066) (239,476) (186,479)
Total Assets 557,847 653,699 701,288 610,345
Total Debt 50,974 50,672 51,005 11,478
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recursion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technolog
Drug Discovery
Salt Lake City, UT
572 As of 2024
00.000
000000000 00.000

000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
Nottingham, United Kingdom
0000 As of 0000
000000000

000000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000000000000
Branford, CT
00 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recursion Pharmaceuticals Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom 0000 000000000
BioXcel Corporation Branford, CT 00
BenevolentAI Formerly PE-Backed London, United Kingdom 000 00000 000000000 00000
Twist Bioscience Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Verge Genomics Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 0 00000
You’re viewing 5 of 31 competitors. Get the full list »

Recursion Pharmaceuticals Patents

Recursion Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240092770-A1 Heterocycle rmb39 modulators Pending 15-Aug-2022 0000000000
US-20230409960-A1 Image embeddings via deep learning and adaptive batch normalization Pending 21-Jun-2022 000000000
US-20220397565-A1 Methods of screening and related systems Pending 10-Jun-2021 00000000000
CA-3217723-A1 Methods of screening and related systems Pending 10-Jun-2021 00000000000
EP-4352510-A1 Methods of screening and related systems Pending 10-Jun-2021 G01N33/5026
To view Recursion Pharmaceuticals’s complete patent history, request access »

Recursion Pharmaceuticals Executive Team (29)

Name Title Board Seat Contact Info
Christopher Gibson Ph.D Co-Founder, Chief Executive Officer & Board Member
Tina Larson Chief Operating Officer, Operations & President
Tina Marriott President & Chief Operating Officer
Michael Secora Ph.D Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ben Mabey Chief Technology Officer
You’re viewing 5 of 29 executive team members. Get the full list »

Recursion Pharmaceuticals Board Members (14)

Name Representing Role Since
Alaa Halawa Mubadala Investment Company Board Observer 000 0000
Blake Borgeson Ph.D Recursion Pharmaceuticals Board Member 000 0000
Dean Li Ph.D Recursion Pharmaceuticals Co-Founder & Board Member 000 0000
James Hardiman DCVC Board Observer 000 0000
Lee Cooper JD Leaps by Bayer Board Observer 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Recursion Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recursion Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cyclica 25-May-2023 0000000000 000.00 Drug Discovery 000000000
Valence Labs 16-May-2023 0000000000 000.00 Drug Discovery 000000000
Enveda Biosciences 22-Jun-2021 00000 0000 0000 Drug Discovery
Vium 28-Jul-2020 Merger/Acquisition 00.00 Discovery Tools (Healthcare) 000000000
To view Recursion Pharmaceuticals’s complete investments and acquisitions history, request access »

Recursion Pharmaceuticals Subsidiaries (3)

Company Name Industry Location Founded
Valence Labs Drug Discovery Montreal, Canada 2018
Vium Discovery Tools (Healthcare) San Mateo, CA 0000
Cyclica Drug Discovery Toronto, Canada 0000
To view Recursion Pharmaceuticals’s complete subsidiaries history, request access »

Recursion Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

13.92 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

0.00

Percentile

Biotechnology

Subindustry

0. of 405

Rank

0.00

Percentile

To view Recursion Pharmaceuticals’s complete esg history, request access »

Recursion Pharmaceuticals FAQs

  • When was Recursion Pharmaceuticals founded?

    Recursion Pharmaceuticals was founded in 2013.

  • Who is the founder of Recursion Pharmaceuticals?

    Christopher Gibson Ph.D and Dean Li Ph.D are the founders of Recursion Pharmaceuticals.

  • Who is the CEO of Recursion Pharmaceuticals?

    Christopher Gibson Ph.D is the CEO of Recursion Pharmaceuticals.

  • Where is Recursion Pharmaceuticals headquartered?

    Recursion Pharmaceuticals is headquartered in Salt Lake City, UT.

  • What is the size of Recursion Pharmaceuticals?

    Recursion Pharmaceuticals has 572 total employees.

  • What industry is Recursion Pharmaceuticals in?

    Recursion Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Recursion Pharmaceuticals a private or public company?

    Recursion Pharmaceuticals is a Public company.

  • What is Recursion Pharmaceuticals’s stock symbol?

    The ticker symbol for Recursion Pharmaceuticals is RXRX.

  • What is the current stock price of Recursion Pharmaceuticals?

    As of 14-Jun-2024 the stock price of Recursion Pharmaceuticals is $9.26.

  • What is the current market cap of Recursion Pharmaceuticals?

    The current market capitalization of Recursion Pharmaceuticals is $2.2B.

  • What is Recursion Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Recursion Pharmaceuticals is $45.2M.

  • Who are Recursion Pharmaceuticals’s competitors?

    Sygnature Discovery, BioXcel, BenevolentAI, Twist Bioscience, and Verge Genomics are some of the 31 competitors of Recursion Pharmaceuticals.

  • What is Recursion Pharmaceuticals’s annual earnings per share (EPS)?

    Recursion Pharmaceuticals’s EPS for 12 months was -$1.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »